sb 203580 has been researched along with Adenocarcinoma, Papillary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arimoto-Ishida, E; Hisamoto, K; Ikebuchi, Y; Kimura, A; Mabuchi, S; Murata, Y; Nishio, Y; Ohmichi, M; Takahashi, K; Tasaka, K | 1 |
| Garcia-Rojas, R; Jackson, RM | 1 |
2 other study(ies) available for sb 203580 and Adenocarcinoma, Papillary
| Article | Year |
|---|---|
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antioxidants; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flavonoids; G1 Phase; Gene Expression; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyridines; Receptors, Estrogen; Tamoxifen | 2004 |
Kinase activity, heat shock protein 27 phosphorylation, and lung epithelial cell glutathione.
Topics: Adenocarcinoma, Papillary; Cell Line, Tumor; Enzyme Inhibitors; Epithelial Cells; Glutathione; Glutathione Disulfide; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Naphthoquinones; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Respiratory Mucosa; Transfection | 2008 |